Status:
COMPLETED
Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema
Lead Sponsor:
Wills Eye
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Melanoma is the most common primary tumour which occurs inside the eye. For over 20-years, it has been possible, in many cases, to use local delivery of radiation to the eye to treat this type of tumo...
Detailed Description
BACKGROUND: Uveal melanoma is the most common primary intraocular malignancy. Plaque radiation (brachytherapy) has emerged as the most common treatment in the current management of uveal melanoma, but...
Eligibility Criteria
Inclusion
- Uveal melanoma new diagnosis, undergoing plaque radiation treatment
Exclusion
- Pre-existing macular disease
- age-related macular degeneration
- diabetic maculopathy
- pre-existing retinal vascular occlusion
- macular hole
- surface wrinkling retinopathy
- prior retinal detachment
- media opacities precluding accurate OCT imaging
- known 'steroid responder'
- glaucoma
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT00441662
Start Date
November 1 2004
End Date
May 1 2007
Last Update
March 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ocular Oncology Service, Wills Eye Institute
Philadelphia, Pennsylvania, United States, 19107